Fri, 08 May 2009 14:23:46 -0400 PeerView Press http://www.peerviewpress.com Podcast Maker v1.3.8b - http://www.lemonzdream.com/podcastmaker Thought leader perspectives on current clinical advances in medicine. PeerView Press is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. 2007 PeerView Press,24 West 40th Street, Suite 950, New York, NY 10018 webmaster@peerviewpress.com http://podcast.peerviewpress.com/rheumatologyvideous/vidRheumatologyCME-CNE-CPE_144.jpg http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Rheumatology no PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in rheumatology discuss the latest data on treatment of RA, including the emerging evidence supporting early use of traditional and biologic antirheumatic drugs in undifferentiated arthritis and early stage RA, as well as up-to-date findings regarding the efficacy and safety of T- and B-cell-targeted biologics in RA. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA5362FCr428.m4v http://podcast.peerviewpress.com/rheumatologyvideous/PA05362FCr428.m4v Thu, 19 Mar 2009 13:53:54 -0400 Science no 00:30:40 rheumatoid arthritis, undifferentiated, inflammatory, DMARDs, CCP, abatacept, etanercept, methotrexate, TNF, rituximab PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA05362FCCMEinfo.pdf http://podcast.peerviewpress.com/rheumatologyvideous/PA05362FCCMEinfo.pdf Thu, 19 Mar 2009 13:52:27 -0400 Science no 00:00:00 rheumatoid arthritis, undifferentiated, inflammatory, DMARDs, CCP, abatacept, etanercept, methotrexate, TNF, rituximab PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA04880FCCMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA04880FCCMEinfo.pdf Wed, 27 Aug 2008 09:57:14 -0400 Science no 00:00:00 lupus nephritis, antimalarials, glucocorticoids, NSAIDs, immunosuppressive agents, belimumab, epratuzumab, infliximab, mycophenolate mofetil, rituximab, cyclophosphamide, EXPLORER PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts on SLE review current and emerging treatments, discuss the latest treatment guidelines from EULAR, and propose therapeutic strategies for patients with lupus nephritis. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA04880FCr405.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA04880FCr405.m4v Fri, 01 Aug 2008 09:58:14 -0400 Science no 00:28:44 lupus nephritis, antimalarials, glucocorticoids, NSAIDs, immunosuppressive agents, belimumab, epratuzumab, infliximab, mycophenolate mofetil, rituximab, cyclophosphamide, EXPLORER PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in the treatment of rheumatoid arthritis evaluate recent data on the impact of newer biologics on functional outcomes and quality-of-life parameters. A review of the efficacy and safety of these agents is featured. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FC3r363.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FC3r363.m4v Thu, 10 Apr 2008 15:50:55 -0400 Science no 00:29:34 Rheumatoid arthritis, ACR, AIM, ATTAIN, abatacept, anti-TNF, DANCER, HAQ, mHAQ, MDHAQ, REFLEX, rituximab PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FC3CMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FC3CMEinfo.pdf Thu, 10 Apr 2008 15:50:53 -0400 Science no 00:00:00 Rheumatoid arthritis, ACR, AIM, ATTAIN, abatacept, anti-TNF, DANCER, HAQ, mHAQ, MDHAQ, REFLEX, rituximab PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in the treatment of rheumatoid arthritis (RA) discuss updated safety data associated with the use of abatacept or rituximab in methotrexate- or TNF-antagonist–refractory RA. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FC2r362.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FC2r362.m4v Wed, 27 Feb 2008 16:39:45 -0500 Science no 00:33:20 Rheumatoid, arthritis, biologics, safety, abatacept, rituximab, DMARDs, TNF, antagonists, AIM, SERENE, IMAGE, SUNRISE, DANCER, infusion, reactions PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FC2CMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FC2CMEinfo.pdf Wed, 27 Feb 2008 16:39:41 -0500 Science no 00:00:00 Rheumatoid, arthritis, biologics, safety, abatacept, rituximab, DMARDs, TNF, antagonists, AIM, SERENE, IMAGE, SUNRISE, DANCER, infusion, reactions PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in the treatment of rheumatoid arthritis discuss recent data on the use of abatacept and rituximab in methotrexate- or TNF-antagonist–refractory rheumatoid arthritis. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FC1r361.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FC1r361.m4v Wed, 13 Feb 2008 16:08:44 -0500 Science no 00:25:12 Rheumatoid arthritis, abatacept, rituximab, DANCER, REFLEX, AIM, ATTAIN, ACR, EULAR, radiographic PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FCCMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03791FCCMEinfo.pdf Wed, 13 Feb 2008 16:08:40 -0500 Science no 00:00:00 Rheumatoid arthritis, abatacept, rituximab, DANCER, REFLEX, AIM, ATTAIN, ACR, EULAR, radiographic PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts provide an update on the latest data on efficacy and safety of current and novel biologic therapies for rheumatoid arthritis (RA). Additionally, the activity will provide information from new RA treatment guidelines intended to help physicians understand when to start nonbiologic and biologic therapies in RA. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03799FCs441.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03799FCs441.m4v Fri, 18 Jan 2008 16:40:36 -0500 Science no 00:27:18 CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Rheumatology PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/rheumatology/PA03799FCCMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03799FCCMEinfo.pdf Fri, 18 Jan 2008 16:40:33 -0500 Science no 00:00:00 CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE, Rheumatology PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts in the treatment of fibromyalgia present recent data on its diagnosis and management. Recent research on causes, mechanisms, and genetic markers are also highlighted. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA04159FCr353.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA04159FCr353.m4v Wed, 16 Jan 2008 17:36:28 -0500 Science no 00:28:06 Fibromyalgia, FMS, myofascial pain syndrome, chronic fatigue syndrome, hypothyroidism, depression, posttraumatic stress disorder, ACR criteria, genetic factors, central sensitization, pregabalin, duloxetine, milnacipran, tricyclic antidepressants PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA04159FCCMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA04159FCCMEinfo.pdf Wed, 16 Jan 2008 17:36:25 -0500 Science no 00:00:00 Fibromyalgia, FMS, myofascial pain syndrome, chronic fatigue syndrome, hypothyroidism, depression, posttraumatic stress disorder, ACR criteria, genetic factors, central sensitization, pregabalin, duloxetine, milnacipran, tricyclic antidepressants PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in the treatment of rheumatoid arthritis review recent data on the safety and efficacy of newer biologics for the treatment of patients with this condition. http://podcast.peerviewpress.com/RheumatologyVideoUS/PAO3526FC3r329.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PAO3526FC3r329.m4v Thu, 15 Nov 2007 16:12:21 -0500 Science & Medicine no 00:38:55 Rheumatoid arthritis, RA, EULAR 2007, ACR 2006, abatacept, rituximab, TNF, anti-TNF, non-responder, methotrexate, etanercept, adalimumab, infliximab PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03526FCCMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03526FCCMEinfo.pdf Thu, 15 Nov 2007 16:12:17 -0500 Science & Medicine no 00:00:00 Rheumatoid arthritis, RA, EULAR 2007, ACR 2006, abatacept, rituximab, TNF, anti-TNF, non-responder, methotrexate, etanercept, adalimumab, infliximab PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, an expert discusses treatment of rheumatoid arthritis based on relevant case scenarios, with a main focus on optimal use of biologic therapies in the context of other available treatment options. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03770FCp124.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03770FCp124.m4v Tue, 06 Nov 2007 16:06:52 -0500 Science & Medicine no 00:37:23 Rheumatology, rheumatoid arthritis, DMARDs, TNF inhibitors, B-cell targeted therapy, rituximab, abatacept PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03770FCCMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03770FCCMEinfo.pdf Tue, 06 Nov 2007 16:06:35 -0500 Science & Medicine no 00:00:00 Rheumatology, rheumatoid arthritis, DMARDs, TNF inhibitors, B-cell targeted therapy, rituximab, abatacept PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this CME activity, experts discuss the expanding role of biologic therapies in rheumatoid arthritis (RA). The latest data on clinical efficacy, inhibition of structural damage, and safety from clinical trials evaluating the newer biologic agents in the treatment of RA are reviewed, and clinical implications of these data are evaluated. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03800FCs406.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03800FCs406.m4v Tue, 30 Oct 2007 10:35:05 -0400 Science & Medicine no 00:29:11 Rheumatoid arthritis, RA, biologic therapy, biologics, B-cell targeted therapy, TNF inhibitors, rituximab, abatacept, tocilizumab, EULAR, efficacy, safety, structural damage PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03800FCCMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03800FCCMEinfo.pdf Tue, 30 Oct 2007 10:35:05 -0400 Science & Medicine no 00:00:00 Rheumatoid arthritis, RA, biologic therapy, biologics, B-cell targeted therapy, TNF inhibitors, rituximab, abatacept, tocilizumab, EULAR, efficacy, safety, structural damage PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this educational activity, expert rheumatologists discuss the rationale for the use of anti–T- or anti–B-cell therapies in rheumatoid arthritis that is refractory to methotrexate or tumor necrosis factor (TNF) antagonists. Specific clinical data are presented regarding the efficacy and safety of the fusion protein abatacept or the anti–B-cell monoclonal antibody rituximab in medically refractory cases. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03726FCr314.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03726FCr314.m4v Mon, 01 Oct 2007 12:55:05 -0400 Science & Medicine no 00:29:25 Abatacept, Disease-modifying antirheumatic drug (DMARD), Etanercept, Infliximab, Methotrexate, Rheumatoid arthritis, Rituximab, Tumor necrosis factor (TNF), Tumor necrosis factor (TNF) antagonist PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03726FCCMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03726FCCMEinfo.pdf Mon, 01 Oct 2007 12:55:04 -0400 Science & Medicine no 00:00:00 Abatacept, Disease-modifying antirheumatic drug (DMARD), Etanercept, Infliximab, Methotrexate, Rheumatoid arthritis, Rituximab, Tumor necrosis factor (TNF), Tumor necrosis factor (TNF) antagonist PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in the treatment of rheumatoid arthritis review recent data on the safety and efficacy of newer biologics for the treatment of patients with this condition. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03526FC2r328.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03526FC2r328_2.m4v Mon, 17 Sep 2007 13:55:52 -0400 Science & Medicine no 00:28:24 Rheumatoid arthritis, abatacept, rituximab, biologics, Annual European Congress of Rheumatology EULAR 2007, ACR, American College of Rheumatology, anti-TNF agents, etanercept, infliximab, adalimumab, tocilizumab PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03526FC2CMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03526FC2CMEinfo_2.pdf Mon, 17 Sep 2007 13:55:51 -0400 Science & Medicine no 00:00:00 Rheumatoid arthritis, abatacept, rituximab, biologics, Annual European Congress of Rheumatology EULAR 2007, ACR, American College of Rheumatology, anti-TNF agents, etanercept, infliximab, adalimumab, tocilizumab PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, experts in the treatment of rheumatoid arthritis review recent data on the newer biologics abatacept and rituximab for the management of this condition. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03526FC1r327.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03526FC1r327.m4v Mon, 20 Aug 2007 15:03:51 -0400 Science & Medicine no 00:23:54 Rheumatoid arthritis, abatacept, rituximab, biologics, Annual European Congress of Rheumatology EULAR 2007, ACR, American College of Rheumatology, anti-TNF agents, etanercept, infliximab, adalimumab PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03526FC1CMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03526FC1CMEinfo.pdf Mon, 20 Aug 2007 15:03:50 -0400 Science & Medicine no 00:00:00 Rheumatoid arthritis, abatacept, rituximab, biologics, Annual European Congress of Rheumatology EULAR 2007, ACR, American College of Rheumatology, anti-TNF agents, etanercept, infliximab, adalimumab PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CE information. In this activity, expert rheumatologists discuss the current evidence-based standard for prescribing disease-modifying therapies in advanced SLE, and the rationale for the use of B-cell–targeted therapies in this setting. In addition, updated clinical data regarding the use of these targeted therapies in SLE are presented. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03654FCr294.m4v http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03654FCr294.m4v Mon, 14 May 2007 11:18:43 -0400 Science & Medicine no 00:26:24 A proliferation-inducing ligand (APRIL), Atacicept, Autoantibody, Azothioprine, B cell, Belimumab, B-lymphocyte stimulator (BLyS), British Isles Lupus Assessment Group (BILAG), CD20 antigen, CD22 antigen, Cyclophosphamide, Double-stranded DNA (dsDNA) PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03654FCCMEinfo.pdf http://podcast.peerviewpress.com/RheumatologyVideoUS/PA03654FCCMEinfo.pdf Mon, 14 May 2007 11:18:22 -0400 Science & Medicine no 00:00:00 A proliferation-inducing ligand (APRIL), Atacicept, Autoantibody, Azothioprine, B cell, Belimumab, B-lymphocyte stimulator (BLyS), British Isles Lupus Assessment Group (BILAG), CD20 antigen, CD22 antigen, Cyclophosphamide, Double-stranded DNA (dsDNA)